Overview

A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study will estimate the response rate in patients with advanced or metastatic non-squamous Non-Small Cell Lung Cancer. Patients who don't progress after 4 to 6 cycles of induction treatment with pemetrexed, cisplatin and cetuximab will receive maintenance treatment with pemetrexed and cetuximab.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cetuximab
Cisplatin
Pemetrexed